ベンリスタ点滴静注用 120mg
ベンリスタ点滴静注用 400mg
製品名はすべて、グラクソ・スミスクライン、そのライセンサー、提携パートナーの登録商標です。
製剤写真及びPDF資料は、患者指導の目的に限りダウンロード頂けます。
医療関係者でない場合はコーポレートサイトへアクセスしてください
会員登録を完了しました
GSKproのご登録ありがとうございます。完了メールをご登録アドレス宛にお送りしております。
引き続き、GSKproの会員限定コンテンツをお楽しみください。
Event Registration successful
You now have sucesfully register for the event and you can also access the latest updates, events and resources.
In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Event registration completed - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We'll send you and email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.
Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy the public content on our website
Event Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy the public content on our website
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.